Reset filter

ANZCA Pholcodine Statement September 2023

This statement has been prepared in response to the decision of the Australian Government Therapeutic Goods Administration (TGA) to withdraw pholcodine-containing products from the market. Evidence shows that pholcodine consumption in the 12-month period prior to a general an...

ROSI presentation slides

ROSI branded PowerPoint slide deck that introduces the importance of and reasons for commencing an opioid analgesic stewardship program.

2023 Blue book submission EOI form

Blue book 2023 submission expression of interest form

ANZCA response to ACI perioperative toolkit consultation

College feedback to the Agency for Clinical Innovation’s (ACI) perioperative toolkit.

SAU_Neuraxial-detailed-info_20190819

Neuraxial device advice for practitioners

Advice for anaesthetists and pain medicine practitioners on the introduction of neural/neuraxial devices with connectors compliant with the new international standard ISO 80369-6.

PG58(A)BP Guideline on quality assurance and quality improvement in anaesthesia Background Paper

PG58(A)BP Guideline on quality assurance and quality improvement in anaesthesia Background Paper

PS11(PM) Procedures in Pain Medicine

7-ANZCA-comment-RACP-Obesity-Statement-Mar-2018

Procedures program: Expressions of Interest form

First  < Prev   ... 31 32 33 34 35 36 37 38 39 40 ...   Next >  Last Pages: 34 of 113